⌕
Viridian Therapeutics · VRDN · Nasdaq
Tenet 43 · Weak
Compare
$30.87+1.28%At closeTenet 43 · Weak
$30.87+0.39 (+1.28%)
At close: Nov 13, 2026, 4:00 PM ET· Nasdaq · USD

Viridian Therapeutics (VRDN) Institutional Ownership

Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.

Sources Ownership filingsQuarter ended How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

13F fund flowQuarter ended Jun 30, 2026. Withheld: many filers have already reported a later quarter, so their changes in this quarter are not on file and the counts of new, added, trimmed and closed positions are not shown. These positions are 140 days old; the 45-day figure often quoted is the SEC filing deadline after quarter-end, not the age of the data. The counts above compare each filer’s position with its own previous 13F. The change in the number of filers and in the ownership share is not shown: the filings we read hold only each filer’s latest 13F, so there is no earlier quarter of the same filers to compare against. That is a limit of the source, not a statement about this company.
SHARES HELD BY 13F FILERS
withheld
withheld by our checks · 219 filers, Jun 30, 2026
# 13F FUNDS
219
13F VALUE
$2.5B
136.6M shares
Not reported in the company's filings for this period.
routine sells are usually compensation mechanics; open-market buys are the rarer signal. Rows labelled with another security are the derivative leg of a vest or exercise, not share sales
DateNameRoleTypeSharesPriceSEC filing
Aug 19, 2026Tousignant JenniferChief Legal OfficerDisposed · Open-market sale4,212$24.50↗
Aug 19, 2026Tousignant JenniferChief Legal OfficerAcquired · Option exercise10,000$14.41↗
Aug 19, 2026Tousignant JenniferChief Legal OfficerDisposed · Open-market sale10,000$24.50↗
Aug 19, 2026Tousignant JenniferChief Legal OfficerDisposed · Option exercise10,000Stock Option (Right to Buy)—↗
Aug 14, 2026Tripuraneni RadhikaChief Medical OfficerAcquired · Option exercise40,000$13.21↗
Aug 14, 2026Tripuraneni RadhikaChief Medical OfficerDisposed · Option exercise40,000Stock Option (Right to Buy)—↗
Jul 1, 2026CAIN CHRISTOPHER W.directorAcquired · Grant / award32,341Stock Option (Right to Buy)—↗
Jul 1, 2026Ajer Jeffrey RobertdirectorAcquired · Grant / award32,341Stock Option (Right to Buy)—↗
Jul 1, 2026Moses Jennifer K.directorAcquired · Grant / award32,341Stock Option (Right to Buy)—↗
Jul 1, 2026Gheuens SarahdirectorAcquired · Grant / award32,341Stock Option (Right to Buy)—↗
Jul 1, 2026Kiselak TomasdirectorAcquired · Grant / award32,341Stock Option (Right to Buy)—↗
Jul 1, 2026Morris ArlenedirectorAcquired · Grant / award32,341Stock Option (Right to Buy)—↗
May 11, 2026Fairmount Funds Management LLCdirectorAcquired · Open-market buy1,176,470$17.00↗
Mar 3, 2026Harmon SethChief Financial OfficerDisposed · Tax withholding2,031$30.19↗
Mar 3, 2026Beetham Thomas W.Chief Operating OfficerDisposed · Tax withholding3,048$30.19↗
Mar 3, 2026Tousignant JenniferChief Legal OfficerDisposed · Tax withholding1,675$30.19↗
Mar 3, 2026Mahoney Stephen F.President and CEODisposed · Tax withholding7,408$30.19↗
Mar 3, 2026Tousignant JenniferChief Legal OfficerAcquired · Option exercise5,169—↗
Mar 3, 2026Tousignant JenniferChief Legal OfficerDisposed · Tax withholding1,724$29.32↗
Mar 3, 2026Tousignant JenniferChief Legal OfficerDisposed · Option exercise5,169Restricted Stock Units—↗

* Holdings as reported for Jun 30, 2026, 140 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.

** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.

How many 13F filers hold Viridian Therapeutics?

Viridian Therapeutics was held by 219 13F filers as of Jun 30, 2026.

Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.